Invariant NKT Cells Unleashed: Building a Pipeline for Cutting-Edge Allogeneic Cell Therapies

Time: 11:30 am
day: Day Two


• iNKT-CD19 CAR progressing from discovery towards first-in-human clinical trial against hematological malignancies.

• Combining iNKT-CD19 CAR with a CD19-expressing oncolytic virus to target solid tumors.

• Incorporation of CARs targeting solid tumors into the iNKT platform. Claudin 18.2 as a promising target against gastric and pancreatic tumors.